Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 229Leukemia, Lymphocytic, Chronic, B-Cell 213Leukemia 203Myelodysplastic Syndromes 185Precursor Cell Lymphoblastic Leukemia-Lymphoma 174Lymphoma 148Lymphoma, Non-Hodgkin 142Multiple Myeloma 131Hodgkin Disease 123Lymphoma, Follicular 111Lymphoma, Mantle-Cell 108Lymphoma, Large B-Cell, Diffuse 96Lymphoma, B-Cell, Marginal Zone 89Myeloproliferative Disorders 86Congenital Abnormalities 85Burkitt Lymphoma 85Leukemia, Myelomonocytic, Chronic 77Leukemia, Myelogenous, Chronic, BCR-ABL Positive 75Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myeloid, Accelerated Phase 73Recurrence 63Melanoma 62Lymphoma, Large-Cell, Immunoblastic 61Anemia, Refractory, with Excess of Blasts 60Neoplasms, Plasma Cell 56Waldenstrom Macroglobulinemia 55Primary Myelofibrosis 55Blast Crisis 55Hematologic Neoplasms 45Lymphoma, T-Cell, Cutaneous 42

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelin-positive Advanced Refractory Solid Tumors × fludarabine phosphate × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡